N-acetyl mefloquine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-acetyl mefloquine
• 英文别名: Melfoquine, N-acetyl-；1-[2-[[2,8-bis(trifluoromethyl)quinolin-4-yl]-hydroxymethyl]piperidin-1-yl]ethanone
• 化学式: C₁₉H₁₈F₆N₂O₂
• 分子量: 420.355
• InChiKey: XIBOCEIJCDXHKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  Acetic acid (1-acetyl-piperidin-2-yl)-(2,8-bis-trifluoromethyl-quinolin-4-yl)-methyl ester 在 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 生成 N-acetyl mefloquine
  参考文献：
  名称：

  Roesner, Manfred; Brossi, Arnold; Silverton, James V., Heterocycles, 1981, vol. 15, # 2, p. 925 - 933

  摘要：

  DOI：

文献信息

• Methods and compositions for treating diseases associated with pathogenic proteins
  申请人：Chiang K. Peter

  公开号：US20070179123A1

  公开（公告）日：2007-08-02

  Methods and compositions are provided comprising a therapeutically effective amount of a compound of formula I wherein R 1-4 , W, X, Y and Z are as defined in the specification, for inhibiting and treating diseases and disorders associated with pathogenic proteins causing neurodegenerative diseases and amyloid diseases, such as protease resistant prion proteins (PrP Sc ) and those associated with transmissible spongiform encephalopathies (TSEs), Alzheimer's Disease, amyloidosis, and the like.

  提供了一种方法和组合物，包括公式I中化合物的治疗有效量，其中R1-4，W，X，Y和Z如规范中所定义，用于抑制和治疗与致病蛋白质相关的疾病和障碍，这些致病蛋白质导致神经退行性疾病和淀粉样疾病，如蛋白酶抵抗性朊病毒蛋白（PrPSc）和与可传播性海绵状脑病（TSEs），阿尔茨海默病，淀粉样变性等相关的蛋白质。
• 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS (II)
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1107761A2

  公开（公告）日：2001-06-20
• [EN] 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS.(II)<br/>[FR] DERIVES DE 4-QUINOLINEMETHANOL UTILISES COMME ANTAGONISTES (II) DU RECEPTEUR DE PURINE
  申请人：CEREBRUS PHARM LTD

  公开号：WO2000013682A2

  公开（公告）日：2000-03-16

  Wherein: R1 is hydrogen or alkyl; R2 is selected from hydrogen, alkyl, aryl and 4,5,6,7 or 8 membered satured and partially unsaturated heterocyclic rings containing one or more heteroatoms selected from O, S and N; R3 and R4 are independently selected from hydrogen, alkyl, aryl, COR13, CO2R13, CONR13R14, CONR13NR14R15, SO2R13, SO2NR13R14, SO2NR13NR14R15 or may form a ring. Or R1 and R4 together may form a heterocyclic ring or R2 and R3 together may form a heterocyclic ring. R5 and R6 are independently selected from hydrogen, alkyl, aryl and heterocyclic with the proviso that where R3 and R5 together form a ring, then R3, and R4 do not also form a ring; or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, such as a movement disorder, for example, Parkinson's Disease or progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorder-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.
• Roesner, Manfred; Brossi, Arnold; Silverton, James V., Heterocycles, <hi>1981</hi>, vol. 15, # 2, p. 925 - 933
  作者：Roesner, Manfred、Brossi, Arnold、Silverton, James V.

  DOI：——

  日期：——